Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2024-04-05 | 2024-04-04 |
| Drug Identification Number | 02403943 | 02403943 |
| Brand name | NEUPRO | NEUPRO |
| Common or Proper name | Neupro 8mg 30 PAT iRT CA | Neupro 8mg 30 PAT iRT CA |
| Company Name | UCB CANADA INC | UCB CANADA INC |
| Ingredients | ROTIGOTINE | ROTIGOTINE |
| Strength(s) | 8MG | 8MG |
| Dosage form(s) | PATCH | PATCH |
| Route of administration | TRANSDERMAL TRANSDERMAL | TRANSDERMAL TRANSDERMAL |
| Packaging size | 30 | 30 |
| ATC code | N04BC | N04BC |
| ATC description | ||
| Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | 2024-04-02 | 2024-04-02 |
| Actual start date | 2024-04-03 | 2024-04-03 |
| Estimated end date | 2024-04-16 | 2024-04-16 |
| Actual end date | 2024-04-04 | |
| Shortage status | Resolved | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | Shortage due to delay in review and lot release process. No QA event expected. | Shortage due to delay in review and lot release process. No QA event expected. |
| Health Canada comments |